• PDF: Delivered by email usually within 48 UK business hours.

Alizyme plc (AZM) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:84

Alizyme plc (AZM) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Alizyme plc (AZM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Alizyme plc is a specialty biopharmaceutical development company that primarily focuses on the therapeutic areas of metabolic disorders, gastrointestinal disorders and cancer supportive care. It is engaged in developing products for the treatment and management of obesity and related conditions, such as type 2 diabetes, of gastrointestinal disorders involving inflammation, such as ulcerative colitis, and of the gastrointestinal side effects of cancer therapy, such as mucositis. Its products in development include Cetilistat for the treatment of obesity and associated conditions, COLAL-PRED for the treatment of ulcerative colitis and ATL-104 for mucositis. On 21 December 2009 both Alizyme plc and Alizyme Therapeutics Limited converted from being in administration to liquidation.The company is headquartered in Cambridge, United Kingdom.

Alizyme plc (AZM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.

This report covers the following industry codes:
SIC Code: 2834
NAICS Code: 325412

  • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deal Details
    • Asset Purchase
    • Alizyme Acquires COLAL Drug Delivery Technology From BTG
    • Partnerships
    • Alizyme Enters Into Co-Development Agreement With TSD Japan
    • Licensing Agreements
    • Norgine Enters Into Licensing Agreement With Alizyme
    • Alizyme Enters Into Licensing Agreement With Prometheus
    • Equity Offering
    • Alizyme Completes Private Placement Of $19.89 Million
    • Alizyme Completes Private Placement Of $28.33 Million
    • Alizyme Completes Private Placement Of $58.58 Million
    • Alizyme Completes Private Placement Of $4.42 Million
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Recent Developments
    • Financial Announcements
    • Nov 19, 2008: Interim Management Statement
    • Aug 29, 2008: August 2008 Alizyme Plc Interim Results
    • May 20, 2008: Alizyme Plc Interim Management Statement
    • Mar 06, 2008: Preliminary Results For The Year Ended 31 December 2006
    • Jul 19, 2007: Alizyme Plc Interim Results
    • May 16, 2007: 2006 Annual Report And Accounts & Agm Notification
    • Feb 19, 2007: Preliminary Results For The Year Ended 31 December 2006
    • Aug 09, 2006: Interim Results For The Six Months Ended 30 June 2006
    • Mar 10, 2006: Alizyme Plc Preliminary Results For The Year Ended 31 December 2005
    • Apr 01, 2004: Alizyme Plc - Financial Results For The Year Ended 31 December 2003
    • Aug 08, 2003: Interim Report For The Six Months Ended 30 June 2003
    • Apr 03, 2003: Financial Results For The Year Ended 31 December 2002
    • Jul 25, 2002: Interim Report For The Six Months Ended 30 June 2002
    • Apr 11, 2002: Financial Results For The Year Ended 31 December 2001
    • Apr 02, 2001: Preliminary Results For The Year Ended 31 December 2000
    • Product News
    • Dec 22, 2008: Takeda Commence Cetilistat (Atl-962) Phase Iii Programme In Japan
    • Dec 19, 2003: Alizyme Granted Ctx For Phase Iia Clinical Trial For Atl-104 For Mucositis
    • Dec 17, 2001: Colal-Pred Completes Dosing In Phase Ii Trial
    • Dec 17, 2001: Obesity Drug Successfully Completes Phase I Clinical Development Programme
    • Dec 12, 2005: Alizyme Announces Preliminary Results From Its Successful Phase Iib Clinical Trial Of Cetilistat In Obese Diabetics
    • Nov 09, 2005: Alizyme Successfully Completes Clinical Trial For Cetilistat In The Usa
    • Oct 08, 2007: Phase Iii Clinical Product Development Update
    • Sep 27, 2004: Alizyme Granted Authorisation For Phase Iib Clinical Trial Of Atl-962 In Obese Diabetics
    • Sep 27, 2001: Alizyme Starts Clinical Development Of Mucositis Drug Atl-104
    • Sep 25, 2002: Alizyme Completes Patient Recruitment In Phase Iib Clinical Trial Of Renzapride In Irritable Bowel Syndrome
    • Sep 24, 2003: Alizyme Announces Successful Preliminary Results Of Its Phase Iib Clinical Trial Of Renzapride In Mixed-Symptom Ibs And An Update Of The Renzapride Ibs Development Programme
    • Sep 19, 2003: Alizyme Announces Successful Preliminary Results From Its Phase Iib Obesity Clinical Trial
    • Sep 17, 2001: Alizyme Receives Approval For phase Iib Clinical Trial In Ibs
    • Sep 16, 2008: Takeda Milestone Payment
    • Aug 27, 2002: Alizyme Presents Phase Ib Clinical Trial Results For Atl-962 At International Congress Of Obesity
    • Aug 02, 2006: Alizyme Announces Successful End Of Phase Ii Meeting With Fda For Cetilistat
    • Aug 02, 2005: Recruitment Completed For Phase I Clinical Trial Of Cetilistat In Obese Volunteers In The Usa
    • Jul 24, 2008: Alizyme Announces Headline Results From Its European Phase Iii Clinical Trial Of Colal-Pred
    • Jul 14, 2005: 14 July 2005 - Alizyme Plc, Patient Recruitment Completed For Phase Iib Clinical Trial Of Cetilistat In Obese Diabetics
    • Jul 07, 2005: Alizyme Reaches Agreement With Fda For Renzapride Phase Iii Clinical Trial
    • Jun 19, 2002: Alizyme Granted Ctx For Phase Iib Clinical Trial For Atl-962 For Obesity
    • May 20, 2008: Commencement Of Phase Ii Study For Colal-Pred In The Us
    • Apr 24, 2003: Alizyme Announces Preliminary Results Of Successful Phase Iib Clinical Trial Of Renzapride In Irritable Bowel Syndrome
    • Apr 23, 2008: Results From Renzapride
    • Apr 21, 2005: Alizyme Successfully Completes Thorough Cardiovascular Safety Clinical Trial For Renzapride
    • Apr 11, 2002: Alizyme To Commence Clinical Trial For Renzapride In Irritable Bowel Syndrome Patients In Usa
    • Mar 27, 2002: Alizyme Obtains Approval For Phase Ib Clinical Trial Of Atl-104 In Mucositis
    • Mar 19, 2003: Alizyme Completes Patient Recruitment In Phase Iib Clinical Trial Of Renzapride In Irritable Bowel Syndrome
    • Mar 18, 2005: Alizyme Acquires Patent And Intellectual Property Rights To Colal Drug Delivery Technology From Btg
    • Mar 15, 2005: Alizyme Obtains Approval For A European Phase Iii Clinical Trial Of Colal-Pred For The Treatment Of Ulcerative Colitis
    • Mar 06, 2008: Cetilistat Phase Iii Development Plan
    • Mar 02, 2006: Alizyme Announces Successful Preliminary Results From Its Phase Iia Clinical Trial Of Atl-104 For Mucositis
    • Feb 14, 2002: Alizyme Announces Positive Phase Ii Clinicaltrial Results For Treatment Of Ulcerative Colitis With Colal-Pred
    • Feb 14, 2002: Alizyme Obtains Approval For Phase Iii Clinical Trial Of Colal-Pred In Maintenance Of Remission Of Ulcerative Colitis
    • Jan 31, 2005: Alizyme Opens Investigational New Drug Application For Clinical Trial Of Atl-962 In Usa
    • Jan 31, 2002: Alizyme Granted Approval For A Phase Iib Study Of Atl-1251 In Mixed Symptom Irritable Bowel Syndrome Patients
    • Jan 17, 2002: Successful Completion Of Phase Ia Clinical Trial Of Mucositis Drug Atl-104
    • Jan 12, 2004: Alizyme Successfully Completes Clinical Trial For Renzapride In Irritable Bowel Syndrome Patients In Usa
    • Jan 12, 2004: Alizyme Files New Patent Application For Renzapride
    • Jan 08, 2001: Alizyme Announces Positive Phase Ib Clinical Trial Results with Obesity Drug Atl-962
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 84
  • List of Tables
    • Alizyme plc, Pharmaceuticals & Healthcare, Key Facts, 2008
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Alizyme plc, Deals By Therapy Area, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Alizyme Acquires COLAL Drug Delivery Technology From BTG
    • Alizyme Enters Into Co-Development Agreement With TSD Japan
    • Norgine Enters Into Licensing Agreement With Alizyme
    • Alizyme Enters Into Licensing Agreement With Prometheus
    • Alizyme Completes Private Placement Of $19.89 Million
    • Alizyme Completes Private Placement Of $28.33 Million
    • Alizyme Completes Private Placement Of $58.58 Million
    • Alizyme Completes Private Placement Of $4.42 Million
    • Alizyme plc, Key Employees 32
  • List of Figures
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals by Year, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Alizyme plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about Alizyme plc (AZM) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha